Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

8.0K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
8.0K
Hybridoma Technology01:31

Hybridoma Technology

18.3K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advances in light-based 3D bioprinting.

Biofabrication·2026
Same author

Autoantibodies and Relapse of Systemic Sclerosis After Autologous Hematopoietic Cell Transplantation.

The Journal of rheumatology·2026
Same author

Impact of measurable residual disease on outcomes using a modified DFCI protocol for adults with BCR-ABL negative acute lymphoblastic leukemia.

Leukemia research·2026
Same author

Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias.

Blood advances·2026
Same author

Population Pharmacokinetics and Optimal Exposure of Antithymocyte Globulin in Myeloablative Hematopoietic Cell Transplantation.

Transplantation and cellular therapy·2026
Same author

Quality of Life and Comorbidities of Long-Term Survivors of Allogeneic Hematopoietic Cell Transplant Versus Their Siblings.

Transplantation and cellular therapy·2025

Related Experiment Video

Updated: Mar 27, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

Antithymocyte Globulin at Clinically Relevant Concentrations Kills Leukemic Blasts.

Rosy Dabas1, Rachelle Lee1, Maria Theresa Servito1

  • 1Department of Medicine, University of Calgary, Calgary, Alberta, Canada.

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|January 19, 2016
PubMed
Summary

Rabbit antithymocyte globulin (ATG) demonstrates direct anti-leukemic activity by killing acute leukemia blasts in vitro. This finding suggests potential for personalized ATG administration in hematopoietic cell transplantation, as ATG does not increase relapse risk.

Keywords:
Acute leukemiaAllogeneic hematopoietic cell transplantationAntithymocyte globulinGraft-versus-host diseaseRelapse

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K

Related Experiment Videos

Last Updated: Mar 27, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Rabbit antithymocyte globulin (ATG) is used for graft-versus-host disease (GVHD) prophylaxis in hematopoietic cell transplantation (HCT).
  • Unlike other agents, ATG does not appear to increase relapse risk post-HCT, but the underlying mechanism remains unclear.
  • A potential antileukemic effect of ATG has been hypothesized.

Purpose of the Study:

  • To investigate the in vitro antileukemic activity of rabbit antithymocyte globulin (ATG).
  • To determine if ATG, at clinically relevant concentrations, can induce the killing of acute leukemia blasts.
  • To explore the mechanisms of ATG-induced cytotoxicity, including complement-dependent cytotoxicity (CDC) and complement-independent cytotoxicity (CIC).

Main Methods:

  • Collected bone marrow or blood from 36 patients with newly diagnosed acute leukemia.
  • Assessed ATG-induced leukemic blast killing using complement-dependent cytotoxicity (CDC) and complement-independent cytotoxicity (CIC) assays.
  • Incubated blasts with varying concentrations of ATG (1–50 mg/L) and measured cell death.

Main Results:

  • ATG demonstrated dose-dependent killing of leukemic blasts via both CDC and CIC.
  • Median blast killing ranged from 0.3% to 42.2% for CDC and 1.9% to 13.9% for CIC across tested ATG concentrations.
  • Complement-independent cytotoxicity (CIC) suggested direct induction of apoptosis by ATG, with significant inter-patient variability in blast sensitivity.

Conclusions:

  • Rabbit antithymocyte globulin (ATG) exhibits direct in vitro antileukemic activity against acute leukemia blasts at clinically relevant concentrations.
  • The sensitivity of leukemic blasts to ATG varies considerably, indicating potential for personalized treatment strategies.
  • These findings may explain why ATG does not increase relapse risk and could inform optimized therapeutic approaches in HCT.